Peter Vanlandschoot

2.6k total citations · 1 hit paper
44 papers, 2.1k citations indexed

About

Peter Vanlandschoot is a scholar working on Epidemiology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Peter Vanlandschoot has authored 44 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Epidemiology, 22 papers in Immunology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Peter Vanlandschoot's work include Hepatitis B Virus Studies (18 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Immunotherapy and Immune Responses (10 papers). Peter Vanlandschoot is often cited by papers focused on Hepatitis B Virus Studies (18 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Immunotherapy and Immune Responses (10 papers). Peter Vanlandschoot collaborates with scholars based in Belgium, Netherlands and United Kingdom. Peter Vanlandschoot's co-authors include Xavier Saelens, Geert Leroux‐Roels, Willy Min Jou, Walter Fiers, Sabine Neirynck, Tom Deroo, Freya Van Houtte, Bert Schepens, Lorena Itatí Ibañez and Benedikte Serruys and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Peter Vanlandschoot

44 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A universal influenza A vaccine based on the extracellular domain of the M2 protein

1999 627 citations Sabine Neirynck, Tom Deroo et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Vanlandschoot Belgium	22	1.1k	804	696	686	407	44	2.1k
Antonella Folgori Italy	31	1.2k 1.0×	670 0.8×	733 1.1×	580 0.8×	414 1.0×	55	2.6k
Denise M. McKinney United States	25	687 0.6×	1.1k 1.4×	899 1.3×	287 0.4×	490 1.2×	32	2.2k
Lynda Tussey United States	23	1.1k 1.0×	1.7k 2.1×	773 1.1×	243 0.4×	458 1.1×	35	2.7k
Glenn Ishioka United States	24	591 0.5×	1.5k 1.8×	844 1.2×	363 0.5×	265 0.7×	45	2.3k
Marie‐Louise Michel France	31	2.1k 1.9×	1.3k 1.6×	795 1.1×	175 0.3×	534 1.3×	70	3.0k
Mark Throsby Netherlands	23	1.5k 1.3×	985 1.2×	871 1.3×	813 1.2×	774 1.9×	46	3.3k
Erik Depla Belgium	23	1.6k 1.4×	485 0.6×	482 0.7×	697 1.0×	308 0.8×	48	2.7k
Andrea Jegerlehner Switzerland	17	747 0.7×	930 1.2×	424 0.6×	299 0.4×	333 0.8×	17	1.7k
Ira Berkower United States	21	356 0.3×	803 1.0×	942 1.4×	534 0.8×	173 0.4×	45	1.9k
Carol D. Weiss United States	27	775 0.7×	756 0.9×	669 1.0×	398 0.6×	1.2k 3.0×	65	2.6k

Countries citing papers authored by Peter Vanlandschoot

Since Specialization

Citations

This map shows the geographic impact of Peter Vanlandschoot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Vanlandschoot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Vanlandschoot more than expected).

Fields of papers citing papers by Peter Vanlandschoot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Vanlandschoot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Vanlandschoot. The network helps show where Peter Vanlandschoot may publish in the future.

Co-authorship network of co-authors of Peter Vanlandschoot

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Vanlandschoot. A scholar is included among the top collaborators of Peter Vanlandschoot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Vanlandschoot. Peter Vanlandschoot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hultberg, Anna, Heidi Rommelaere, Angela Wittelsberger, et al.. (2014). Protective Effect of Different Anti-Rabies Virus VHH Constructs against Rabies Disease in Mice. PLoS ONE. 9(10). e109367–e109367. 34 indexed citations

Andersen, Jan Terje, María González-Pajuelo, Stian Foss, et al.. (2013). Selection of Nanobodies that Target Human Neonatal Fc Receptor. Scientific Reports. 3(1). 1118–1118. 8 indexed citations

Maussang, David, Francis J. Descamps, Catelijne Stortelers, et al.. (2013). Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growth in Vivo. Journal of Biological Chemistry. 288(41). 29562–29572. 124 indexed citations

Schepens, Bert, Lorena Itatí Ibañez, Anna Hultberg, et al.. (2011). Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion. The Journal of Infectious Diseases. 204(11). 1692–1701. 43 indexed citations

Vlist, Els J. van der, Peter Vanlandschoot, Pascal Merchiers, et al.. (2011). Enhancement of Polymeric Immunoglobulin Receptor Transcytosis by Biparatopic VHH. PLoS ONE. 6(10). e26299–e26299. 25 indexed citations

Steyaert, Sophia, Lieven Verhoye, Els Beirnaert, et al.. (2007). The intraspleen huPBL NOD/SCID model to study the human HIV-specific antibody response selected in the course of natural infection. Journal of Immunological Methods. 320(1-2). 49–57. 2 indexed citations

Broos, Katleen, Peter Vanlandschoot, Marleen Maras, et al.. (2007). Expression, purification and characterization of full-length RNA-free hepatitis B core particles. Protein Expression and Purification. 54(1). 30–37. 17 indexed citations

Vanlandschoot, Peter, Freya Van Houtte, Benedikte Serruys, & Geert Leroux‐Roels. (2004). The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate. Journal of General Virology. 86(1). 75–84. 32 indexed citations

Vanlandschoot, Peter, Freya Van Houtte, Frans J. Hoek, Rienk Nieuwland, & Geert Leroux–Roels. (2003). Saccharomyces cerevisiae‐derived HBsAg preparations differ in their attachment to monocytes, immune‐suppressive potential, and T‐cell immunogenicity. Journal of Medical Virology. 70(4). 513–519. 14 indexed citations

10.

Steyaert, Sophia, Peter Vanlandschoot, Hans Van Vlierberghe, Helmut M. Diepolder, & Geert Leroux‐Roels. (2003). Soluble CD14 levels are increased and inversely correlated with the levels of hepatitis B surface antigen in chronic hepatitis B patients. Journal of Medical Virology. 71(2). 188–194. 10 indexed citations

11.

Meuleman, Philip, Peter Vanlandschoot, & Geert Leroux‐Roels. (2003). A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice. Biochemical and Biophysical Research Communications. 308(2). 375–378. 43 indexed citations

12.

Vanlandschoot, Peter & Geert Leroux‐Roels. (2003). Viral apoptotic mimicry: an immune evasion strategy developed by the hepatitis B virus?. Trends in Immunology. 24(3). 144–147. 53 indexed citations

13.

Vanlandschoot, Peter, et al.. (2002). Recombinant HBsAg, an apoptotic-like lipoprotein, interferes with the LPS-induced activation of ERK-1/2 and JNK-1/2 in monocytes. Biochemical and Biophysical Research Communications. 297(3). 486–491. 26 indexed citations

14.

Leroux‐Roels, Geert, Tinghua Cao, Philip Meuleman, et al.. (2001). PREVENTION OF HEPATITIS B INFECTIONS : VACCINATION AND ITS LIMITATIONS. Acta Clinica Belgica. 56(4). 209–219. 16 indexed citations

15.

Neirynck, Sabine, Tom Deroo, Xavier Saelens, et al.. (1999). A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Medicine. 5(10). 1157–1163. 627 indexed citations breakdown →

16.

Martinet, Wim, Tom Deroo, Xavier Saelens, et al.. (1998). Evaluation of recombinant A/Victoria/3/75 (H3N2) influenza neuraminidase mutants as potential broad-spectrum subunit vaccines against influenza A. Archives of Virology. 143(10). 2011–2019. 3 indexed citations

17.

Vanlandschoot, Peter, et al.. (1998). An antibody which binds to the membrane-proximal end of influenza virus haemagglutinin (H3 subtype) inhibits the low-pH-induced conformational change and cell-cell fusion but does not neutralize virus.. Journal of General Virology. 79(7). 1781–1791. 16 indexed citations

18.

Vanlandschoot, Peter, Els Beirnaert, Sabine Neirynck, et al.. (1996). Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells. Archives of Virology. 141(9). 1715–1726. 18 indexed citations

19.

Vanlandschoot, Peter, Els Beirnaert, Sylvia Dewilde, et al.. (1995). A Fairly Conserved Epitope on the Hemagglutinin of Influenza A (H3N2) Virus with Variable Accessibility to Neutralizing Antibody. Virology. 212(2). 526–534. 12 indexed citations

20.

Vanlandschoot, Peter, Geert Maertens, Willy Min Jou, & Walter Fiers. (1993). Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus. Vaccine. 11(12). 1185–1187. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact